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ABSTRACT: The emergence of a new class of novel
psychoactive substances, N-benzyl-substituted phenethyl-
amine derivatives so-called “NBOMes” or “Smiles”, in the
recreational drug market has forced the development of new
sensitive analytical methodologies for their detection and
quantitation. NBOMes’ hallucinogenic eﬀects mimic those of
the illegal psychedelic drug lysergic acid diethylamide (LSD)
and are typically sold as LSD on blotter papers, resulting in a
remarkable number of fatalities worldwide. In this article, four
halide derivatives of NBOMe, namely, 2-(4-ﬂuoro-2,5-
dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine, 2-(4-
chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-
amine , 2 - (4 -b romo-2 ,5 -d imethoxypheny l ) -N - (2 -
methoxybenzyl)ethan-1-amine, and 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine, were detected and
quantiﬁed simultaneously using a high-performance liquid chromatographic method, and two detection systems were
compared: photodiode array detection (detection system I) and amperometric detection via a commercially available impinging
jet ﬂow-cell system incorporating embedded graphite screen-printed macroelectrodes (detection system II). Under optimized
experimental conditions, linear calibration plots were obtained in the concentration range of 10−300 and 20−300 μg mL−1, for
detection systems I and II, respectively. Detection limit (limit of detection) values were between 4.6−6.7 and 9.7−18 μg mL−1,
for detection systems I and II, respectively. Both detectors were employed for the analysis of the four NBOMe derivatives in the
bulk form, in the presence of LSD and adulterants commonly found in street samples (e.g. paracetamol, caﬀeine, and
benzocaine). Furthermore, the method was applied for the analysis of simulated blotter papers, and the obtained percentage
recoveries were satisfactory, emphasizing its advantageous applicability for the routine analysis of NBOMes in forensic
laboratories.
■ INTRODUCTION
Over the last decade, the use of the so-called new psychoactive
substances (NPSs) has escalated in an unprecedented rate
worldwide, posing a signiﬁcant risk to public health and to
drug control agencies.1 NPSs are considered to be legal
alternatives to illicit drugs and are synthetically designed to
mimic their structure and euphoric eﬀects but are not
controlled under the Misuse of Drug Act.2 By the beginning
of 2010, a new group of NPSs, commonly described as
“NBOMes”, “N-Bombs”, “Smiles”, or “Solaris”, has emerged
into the drug market and Internet vendors, resulting in several
cases of intoxication and fatalities.3−8
NBOMes are N-benzylmethoxy-derivatives of the 2C−X
series of psychoactive phenethylamines with methoxy sub-
stitutions at positions 2 and 5 and a substitution at position 4,
often consisting of a halogen (i.e., ﬂuoride, chloride, bromide,
or iodide).9 The four most common NBOMe derivatives
include (see Scheme 1) 2-(4-ﬂuoro-2,5-dimethoxyphenyl)-N-
(2-methoxybenzyl)ethan-1-amine (2a, 25F-NBOMe), 2-(4-
chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-
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amine (2b, 25C-NBOMe·HCl), 2-(4-bromo-2,5-dimethoxy-
phenyl)-N-(2-methoxybenzyl)ethan-1-amine (2c, 25B-
NBOMe), and 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethan-1-amine (2d, 25I-NBOMe), which is
the most popular member of this family among drug abusers.9
They are potent agonist of the 5-HT2A receptor, and even
doses in micrograms can produce psychoactive eﬀects.10
NBOMes were ﬁrst synthesized in the early 2000s by Ralf
Heim as a pharmacological tool to study the 5-HT2A
receptor.11 However, NBOMe’s use for recreational purposes
had never been reported before 2010 when they started to be
available through the Internet.9 They are considered as
hallucinogenic stimulants that can induce euphoria, hallucina-
tion, agitation, tachycardia, serotonin-like syndrome, seizures,
intoxication, and eventually death.5,12−14 These hallucinogenic
properties resemble those of lysergic acid diethylamide (LSD)
(Scheme 1); wherefore, they are commonly sold as LSD on
blotter papers taken sublingually or by nasal insuﬄations.14−17
In 2013, the U.S. Drug Enforcement Administration
temporarily controlled 2b−d as schedule I illegal drugs, for 2
years under the Controlled Substances Act.18 In June 2014, the
UK permanently controlled NBOMes and listed them as class
A substances under the Misuse of Drugs Act (1971).19 Later,
in November 2014, the World Health Organization in Geneva
has placed NBOMe derivatives under international control.20
Currently, the U.S. is listing the previously mentioned NBOMe
derivatives under schedule I controlled substances according to
the Electronic Code of Federal Regulations (e-CFR) published
in November 2018.21 Hence, there is a requirement for the
development of simple analytical methodologies for the
detection and quantiﬁcation of such illicit drugs to restrict
their commercialization and abuse. Analysis of NBOMe
derivatives, by validated analytical procedures or in individual
case reports, has been extensively performed using a range of
analytical approaches (see Table 1 for a summary), such as
liquid chromatography−tandem mass spectrometry (LC−MS/
MS),11,22−31 ultraperformance liquid chromatography−tandem
mass spectrometry (UPLC−MS/MS),4,32−34 gas chromatog-
raphy−mass spectrometry (GC−MS),15 and paper spray
ionization-mass spectrometry (PSI-MS).35 In addition to
attenuated total reﬂection-Fourier transform infrared spectros-
copy (ATR-FTIR),36 high-performance liquid chromatogra-
phy-photodiode array detection (HPLC-DAD)37 and high-
performance thin-layer chromatography (HPTLC)38,39 have
been previously introduced as standardized protocols for the
qualitative and/or the quantitative analysis of NBOMes (Table
1). Other approaches have reported the use of electrochemical
methodologies including diﬀerential pulse voltammetry (DPV)
using screen-printed carbon electrodes (SPEs)9 and square
wave voltammetry (SWV) utilizing glassy carbon12 and boron-
doped diamond40,41 as working electrodes. These reported
electrochemical methodologies have the limitation of quantify-
ing NBOMes individually, and they are unable to detect
NBOMes simultaneously in complex samples as present in
forensic scenarios.
Herein, for the ﬁrst time, we report a potential high-
performance liquid chromatographic method using two
detection systems: photodiode array detection (HPLC-DAD)
(detection system I) and amperometric detection (HPLC-AD)
utilizing commercially available impinging jet ﬂow cell
incorporating SPEs (detection system II) for the simultaneous
quantiﬁcation of four NBOMe derivatives (2a−d; Scheme 1).
The proposed analytical methodology was validated according
to the International Conference on Harmonization (ICH)
guidelines for the quantitative analysis of the target analytes
and demonstrated to be suitable for the routine analysis of
NBOMe derivatives in pure forms, in the presence of LSD, and
common adulterants typically found in street samples (e.g.
paracetamol, caﬀeine, and benzocaine), as well as within
simulated blotter papers oﬀering excellent selectivity and
speciﬁcity.
Results and Discussion. First, the cyclic voltammetric
proﬁles of each NBOMe derivative were explored using SPEs
(electrode size: 3.1 mm diameter) in a 0.04 M Britton−
Robinson (B−R) buﬀer at pH 7.0, which is the optimum pH
previously reported by Andrade et al. for the electrochemical
characterization and quantiﬁcation of NBOMe derivatives.9
Figure 1 depicts an overlay of the cyclic voltammograms
obtained for the four NBOMe derivatives, and, as can be seen
in the ﬁgure, each derivative develops two oxidation peaks
(peak I and peak II) at the following potentials (vs Ag/Ag/Cl):
Ep1 ≈ +0.815 V and Ep2 ≈ +0.996 V for 25F-NBOMe (2a), Ep1
≈ +0.817 V and Ep2 ≈ +1.027 V for 25C-NBOMe (2b), Ep1 ≈
+0.829 V and Ep2 ≈ +1.031 V for 25B-NBOMe (2c), and Ep1
≈ +0.80 V and Ep2 ≈ +1.013 V for 25I-NBOMe (2d) (Table
2). Andrade et al. have described the oxidation mechanism of
these drugs occurring on the SPE surface as follows (see
Scheme 2):9 the ﬁrst observed oxidation peak (peak I)
develops as a result of the oxidation of the secondary amine
present in the NBOMe structure into a primary amine, which
will be attached to the electrode surface, in addition to the
generation of an aldehyde. This process involves the removal
of one electron from the amino-nitrogen of the NBOMe
secondary amine. The second oxidation peak (peak II) occurs
due to the replacement of the halogen atom in the NBOMe
compounds by a hydroxyl group, which afterwards produces a
ketone. The latter oxidation step happens via an electron
transfer from the highest-ﬁlled molecular orbital of organic
Scheme 1. Synthesis of 25F-, 25C-, 25B-, and 25I-NBOMe·HCl Derivatives (2a−d) from Their Corresponding
Phenethylamine Hydrochlorides (1a−d)a,b
aReagents and conditions: (i) 2-methoxybenzaldehyde/EtOH/room temperature (rt); (ii) NaBH4/EtOH/rt; (iii) HCl (3 M solution in
cyclopentyl methyl ether). b(3) Chemical structure of illicit lysergic acid diethylamide (LSD).
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halide to the electrode, leading to the formation of cation
radical [RX]+•; this is followed by the ﬁssion of a carbon−
halogen bond to form a carbocation, which will be attacked
nucleophilically by the hydroxyl group and its subsequent
oxidation to a ketone (quinone). Due to the overlap of the
voltammetric signatures of the four NBOMe derivatives, it is
impossible to quantify each drug separately if present together
in a mixture by conventional electrochemical methods when in
a forensic scenario. Therefore, eﬀorts were next directed
toward using high-performance liquid chromatography for the
separation of the target analytes, and quantiﬁcation was carried
out by comparing the sensitivity of two detectors, which are
photodiode array (detection system I) and amperometric
detectors (detection system II).
Optimization of the Experimental and Chromato-
graphic Conditions. Experimental Setup and Conﬁgura-
tion of HPLC-AD System. Since the analytical quantiﬁcation of
NBOMe halide derivatives was achieved herein by comparing
two detection systems, namely, DAD and AD, wherefore, the
order of the detectors and the experimental setup is important
for the optimization of the proposed analytical method. The
most suitable arrangement of the two detectors was made
following Zuway et al. who used the same commercial
impinging jet ﬂow cell for the HPLC amperometric detection
of synthetic cathinones.42 They reported that the optimum
experimental setup can be accomplished by placing the ﬂow-
cell amperometric detection system after the photodiode array
detector and connecting them via poly(tetraﬂuoroethylene)
(PTFE) tubing (230 × 1.6 mm2, i.d. 0.3 mm, internal volume:
16.25 μL). This conﬁguration was proven to be better as it
reduced the system back-pressure and thereby decreased the
ﬂow-cell leakages observed when the amperometric detector
Figure 1. Cyclic voltammograms of 100 μg mL−1 of each of 25F-
NBOMe (2a), 25C-NBOMe (2b), 25B-NBOMe (2c), and 25I-
NBOMe (2d) in a 0.04 M B−R buﬀer (pH 7.0) using SPEs. Scan
rate: 50 mV s−1 vs Ag/AgCl reference electrode. (I) First NBOMes’
oxidation peak; (II) second NBOMes’ oxidation peak.
Table 2. Summary of the Anodic Peak Potentials (Ep1 and
Ep2) of NBOMe Derivatives (2a−d) Obtained Using SPEs vs
Ag/AgCl
peak potential
NBOMe derivatives Ep1 (V) Ep2 (V)
25F-NBOMe (2a) +0.815 +0.996
25C-NBOMe (2b) +0.817 +1.027
25B-NBOMe (2c) +0.829 +1.031
25I-NBOMe (2d) +0.800 +1.013
Scheme 2. Electrochemical Oxidation Mechanism of NBOMe Halide Derivatives Previously Reported by Andrade et al.9
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precedes the UV detector.42 In addition, Zuway et al. reported
using two ﬂow cells of diﬀerent designs, which were the
commercially available impinging jet ﬂow cell and custom-
made iCell channel ﬂow cell. In this work, only the impinging
jet ﬂow cell was used, as Zuway et al. demonstrated that iCell
ﬂow cell has reduced sensitivity as a result of its large internal
chamber volume used with the SPE, which increases the
sample dispersion, diluting the analytes, thus reducing the
SPE’s sensor sensitivity via mass transfer/diﬀusion to the
electrode surface.42−45 Full optimization of all of the
experimental parameters, aﬀecting the separation and
quantitation of the analytes of interests, is described in detail
in the Supporting Information (SI) with the chromatographic
conditions chosen for this study summarized in Table 3.
After optimization of all of the experimental conditions,
typical HPLC-DAD chromatogram and HPLC-AD ampero-
gram are presented in Figure 2A,B, respectively. The order of
elution of the drugs (from the chromatographic column)
depends on their degree of polarity, the more polar derivative,
which is the ﬂuoride; 25F-NBOMe (2a) elutes ﬁrst (tR = 3.83
± 0.02 min) followed by the chloride; 25C-NBOMe (2b) (tR
= 5.96 ± 0.02 min) and then the bromide; 25B-NBOMe (2c)
(tR = 7.01 ± 0.03 min) and eventually the iodide derivative;
25I-NBOMe (2d) elutes last (tR = 9.45 ± 0.05 min). The
amperometric peaks of the target analytes were slightly delayed
by 0.39 s in comparison with their corresponding peaks in the
HPLC-DAD chromatogram; this is due to the PTFE
connection tubing between the HPLC-DAD and the ﬂow
cell accommodating the SPE sensing platform. The retention
times of the analytes of interest within the amperogram were as
follows: 25F-NBOMe (2a) (tR = 3.84 ± 0.02 min), 25C-
NBOMe (2b) (tR = 5.97 ± 0.02 min), 25B-NBOMe (2c) (tR =
7.02 ± 0.03 min), and 25I-NBOMe (2d) (tR = 9.46 ± 0.05
min).
Validation of the Proposed Method. Validation of the
proposed method was performed in accordance with the
International Conference on Harmonization (ICH) guidelines
for the validation of analytical procedures.46 The linearity of
the proposed HPLC-DAD (detection system I) and HPLC-
AD (detection system II) was evaluated by analyzing a series of
diﬀerent concentrations of calibration standards (n = 6).
Calibration curves were constructed by plotting the average of
peak areas (for detection system I) or the average of peak
heights (current, μA) (for detection system II) for each
concentration level of each investigated drug against its
corresponding concentration. The linear regression equations
were generated by the least-squares treatment of the
calibration data and are presented in Tables 4 and 5. Good
linearity of the tested analytical methodology is demonstrated
by the high values of coeﬃcient of regression (r2), which is
≥0.999, for detection system I, and ≥0.997, for detection
system II. When comparing the sensitivity of the two detectors,
it is apparent that detection system I is more sensitive than
detection system II. This can be conﬁrmed by the higher slope
(b) values of the calibration curves of the HPLC-DAD (b =
9.08−23.12) in contrast to those obtained by the HPLC-AD
system (b = 2.37 × 10−3−5.70 × 10−3). Furthermore, the
sensitivity of the accessible linear range of detection system I
Table 3. Summary of the Optimized Experimental Parameters Chosen for the Separation and Quantitation of NBOMe
Derivatives
studied experimental parameter optimized parameter
analytical column ACE 5 C18-AR column (150 × 4.6 mm2 i.d., particle size: 5 μm)
mobile phase isocratic (5 mM ammonium formate + 100 mM KCl:acetonitrile 70:30% v/v)
ionic strength of ammonium formate buﬀer 5 mM
pH of the aqueous phase pH 7
linear velocity of the mobile phase 2.5 mL min−1
column temperature 60 °C
applied potential for amperometric detection (AD) +1.0 V
detection wavelength λ for photodiode array detection (DAD) 205 nm
Figure 2. (A) Representative HPLC-DAD chromatogram of a solution containing 100 μg mL−1 of each of “F”: 25F-NBOMe (2a), “Cl”: 25C-
NBOMe (2b), “Br”: 25B-NBOMe (2c), and “I”: 25I-NBOMe (2d). (B) Representative HPLC-AD amperogram of a solution containing 100 μg
mL−1 of each of F: 25F-NBOMe (2a), Cl: 25C-NBOMe (2b), Br: 25B-NBOMe (2c), and I: 25I-NBOMe (2d). Experimental parameters include
ACE C18-AR column (150 × 4.6 mm2 i.d., particle size: 5 μm), mobile phase: [5 mM ammonium formate + 100 mM KCl (pH 7.0): acetonitrile
70:30 (v/v)], ﬂow rate: 2.5 mL min−1, column temperature: 60 °C, detector wavelength (UV): 205 nm, and potential: +1.0 V.
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(10−300 μg mL−1) slightly surpasses that of detection system
II (20−300 μg mL−1). However, this diﬀerence in sensitivity is
negligible in exchange for the advantage of the amperometric
detector being less expensive and more economic than
Table 4. Summary of HPLC-DAD (Detection System I) Validation Data for the Quantiﬁcation of NBOMe Halide Derivatives
(2a−d) Using ACE C18-AR Column (150 × 4.6 mm2 i.d., Particle Size: 5 μm), Mobile Phase: [5 mM Ammonium Formate +
100 mM KCl (pH 7.0): Acetonitrile 70:30% (v/v)], Flow Rate: 2.5 mL min−1, Column Temperature: 60 °C, and Detector
Wavelength (UV): 205 nm
drug of abuse
parameters 25F-NBOMe (2a) 25C-NBOMe (2b) 25B-NBOMe (2c) 25I-NBOMe (2d)
r2 a 0.999b 0.999c 0.999d 0.999e
af −13.52 −29.79 −41.17 −34.88
bg 9.08 16.38 23.12 15.58
LOD (μg mL−1)h 4.56 5.90 5.14 6.65
Precision (% RSD, n = 6)
10 (μg mL−1) 0.70 0.98 1.14 0.51
20 (μg mL−1) 0.58 1.84 1.78 0.01
50 (μg mL−1) 1.26 1.42 1.00 0.28
100 (μg mL−1) 1.08 0.76 0.65 0.98
150 (μg mL−1) 0.49 0.31 0.38 0.82
200 (μg mL−1) 0.93 0.30 0.36 0.79
300 (μg mL−1) 0.27 0.40 0.47 0.58
System Suitability Parameters
tR ± SD (min)
i (n = 6) 3.83 ± 0.02 5.96 ± 0.02 7.01 ± 0.03 9.45 ± 0.05
RRTj 0.41 0.63 0.74 1
k′k 5.18 8.61 10.31 14.24
N (plates)l 8000 8629 8967 8670
HETP (m)m 1.88 × 10−5 1.74 × 10−5 1.67 × 10−5 1.73 × 10−5
Rs
n 9.97 3.82 6.95
As
o 0.85 0.82 0.85 0.94
αp 1.66 1.20 1.38
ar2: coeﬃcient of regression. by = 9.08x − 13.52. cy = 16.38x − 29.79. dy = 23.12x − 41.17. ey = 15.58x − 34.88. fa: intercept of the regression line
of the calibration curve. gb: slope of the regression line of the calibration curve. hLOD: limit of detection using the formula (3Sy/x)/b.
itR: retention
time in minutes for drugs eluted from the chromatographic column (Detection System I). jRRT: relative retention time (determined with respect
to 25I-NBOMe, 2d, retention time obtained from Detection System I). kk′: capacity factor. lN: number of theoretical plates expressed in plates per
meter. mHETP: height equivalent to the theoretical plate expressed in meter. nRs: resolution between two successive eluted peaks.
oAs: asymmetry
factor. pα: relative retention factor.
Table 5. Summary of HPLC-AD (Detection System II) Validation Data for the Quantiﬁcation of NBOMe Halide Derivatives
(2a−d) Using ACE C18-AR Column (150 × 4.6 mm2 i.d., Particle Size: 5 μm), Mobile Phase: [5 mM Ammonium Formate +
100 mM KCl (pH 7.0): Acetonitrile 70:30% (v/v)], Flow Rate: 2.5 mL min−1, Column Temperature: 60 °C, and Potential:
+1.0 V
drug of abuse
parameters 25F-NBOMe (2a) 25C-NBOMe (2b) 25B-NBOMe (2c) 25I-NBOMe (2d)
r2 a 0.997b 0.998c 0.999d 0.999e
af 14.57 × 10−2 8.93 × 10−2 8.52 × 10−2 4.62 × 10−2
bg 5.70 × 10−3 2.85 × 10−3 3.68 × 10−3 2.37 × 10−3
LOD (μg mL−1)h 17.98 16.52 9.65 10.54
Precision (% RSD, n=6)
20 (μg mL−1) 0.74 0.45 1.84 0.83
50 (μg mL−1) 0.57 0.84 0.97 1.54
100 (μg mL−1) 0.79 0.77 0.69 1.12
150 (μg mL−1) 0.87 0.63 0.97 0.07
200 (μg mL−1) 0.72 0.24 0.27 0.97
300 (μg mL−1) 0.32 0.95 0.53 0.63
System Suitability Parameters
tR ± SD (min)
i (n = 6) 3.84 ± 0.02 5.97 ± 0.02 7.02 ± 0.03 9.46 ± 0.05
RRTj 0.41 0.63 0.74 1
ar2: coeﬃcient of regression. by = 0.0057x + 0.1457. cy = 0.0029x + 0.0893. dy = 0.0037x + 0.085. ey = 0.0024x + 0.0462. fa: intercept of regression
line of the calibration curve. gb: slope of regression line of the calibration curve. hLOD: limit of detection using the formula (3Sy/x)/b.
itR: retention
time in minutes for drugs eluting from the ﬂow cell Detection System II). jRRT: relative retention time (determined with respect to 25I-NBOMe,
2d, retention time obtained from Detection System II).
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photodiode array detector. In both detection systems, HPLC-
DAD (detection system I) and HPLC-AD (detection system
II), the limit of detection (LOD) for each drug was determined
using the following formula: LOD= (3Sy/x)/b, where Sy/x is the
standard deviation of residuals and b is the slope of the
regression line of the calibration curve of each drug. The values
of LOD range from 4.56 to 6.65 and 9.65 to 17.98 μg mL−1,
for detection system I and detection system II, respectively
(Tables 4 and 5). These small values of LOD conﬁrm the
sensitivity of the proposed method. However, by comparing
the LOD of both detectors, we concluded that HPLC-DAD
(detection system I) is more sensitive than HPLC-AD
(detection system II). The repeatability (intraday precision)
of the developed methodology, utilizing both detectors, was
assessed by analyzing each concentration level six times (n =
6), within the same day, in the same laboratory, by the same
analyst using the same equipment. The percentage relative
standard deviation (RSD %) of the obtained results, for both
detectors, was calculated and is presented in Tables 4 and 5.
The RSD % values were <2%, indicating the good agreement
between the individual test results and conﬁrming the
precision of the proposed method. The system suitability
testing is used to evaluate the suitability of the chromato-
graphic system prior to using and is considered as an integral
part of method validation.47 All system suitability parameters
are listed in Tables 4 and 5, and it is evident from the tables
that all of the analytes fulﬁlled the ideal range of system
suitability parameters, proving the high-quality performance of
the proposed chromatographic system and ensuring conﬁdence
in the analytical method. Next, the robustness of the proposed
method was veriﬁed by introducing slight changes in the
method parameters such as column temperature (60 ± 2 °C),
molarity of formate buﬀer (5.0 ± 2.0 mM), and pH of buﬀer
(7.0 ± 0.2 pH units). These variations did not have any
signiﬁcant eﬀect on the measured responses (peak area or peak
heights) as the calculated RSD % for the measured responses
did not exceed 2% in all of the cases (Tables S1 and S2).
Furthermore, the retention time of all of the drugs and the
total run time were not aﬀected when changing the
aforementioned three parameters (Table S1). The selectivity
of the proposed method was examined by testing the
possibility of interference of LSD with the determination of
NBOMEs, as NBOMes are commonly sold on blotter papers
represented as LSD.22 As seen in Figure 3, the LSD did not
interfere with any of the four NBOMe derivatives, as it eluted
early at the beginning of the chromatographic run with
retention times (tR) = 2.77 min in HPLC-DAD (Figure 3A)
and 2.78 min in HPLC-AD (Figure 3B). The resolution (Rs)
between the LSD peak and the next peak in the chromatogram
(25F-NBOMe, 2a) is equivalent to 3.73, which proves the
good selectivity and the successfulness of the proposed
protocol. Further selectivity and speciﬁcity testing employing
adulterants commonly found in street samples and pharma-
ceutical excipients are found in the Supporting Information
(SI).
Forensic Application. Application of the Proposed
Method to Simulated Blotter Papers. Most recreated
NBOMe blotter papers contain higher doses of 500−800 μg
per blotter,22,27 and the dimensions of the seized blotters
usually are in the range of [(0.5 × 0.5)−(1 × 1) cm2].40,41
Therefore, three diﬀerent simulated blotter papers were
laboratory-prepared (each blotter was prepared in triplicate)
using concentrations of 500 and 600 μg per blotter of
NBOMes, and LSD was added in two blotters to simulate real
samples. After the extraction of the drugs from the blotters
with methanol, the dilution of the samples was done to obtain
concentrations within the linearity ranges and then analyses
were carried out; each blotter was analyzed in triplicate.
Depicted in Table 6, each drug eluted at its speciﬁed retention
time (tR) when utilizing detection systems I and II, and the
recovery% (R%) and error% (Er%) ranged from 99 to 101%
and −1 to (+)1%, respectively, emphasizing the high accuracy
of the proposed method. The good precision of the method
was demonstrated by the low RSD% values, which did not
exceed 3%. Furthermore, the standard addition procedure was
applied and the calculated recoveries% ranged from 98 to 102
and 98 to 100% for detection systems I and II, respectively,
conﬁrming the accuracy of the developed method (Table 7).
■ CONCLUSIONS
This work presents, for the ﬁrst time, a simple rapid reliable
chromatographic method utilizing both photodiode array
(detection system I) and amperometric (detection system II)
detectors for the simultaneous qualitative and quantitative
Figure 3. (A) Representative HPLC-DAD chromatogram of a solution containing 100 μg mL−1 of each of LSD, F: 25F-NBOMe (2a), Cl: 25C-
NBOMe (2b), Br: 25B-NBOMe (2c), and I: 25I-NBOMe (2d). (B) Representative HPLC-AD amperogram of a solution containing 100 μg mL−1
of each of LSD, F: 25F-NBOMe (2a), Cl: 25C-NBOMe (2b), Br: 25B-NBOMe (2c), and I: 25I-NBOMe (2d). Experimental parameters include
ACE C18-AR column (150 × 4.6 mm2 i.d., particle size: 5 μm), mobile phase: [5 mM ammonium formate + 100 mM KCl (pH 7.0): acetonitrile
70:30% (v/v)], ﬂow rate: 2.5 mL min−1, column temperature: 60 °C, detector wavelength (UV): 205 nm, and potential: +1.0 V.
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H
analyses of four NBOMe derivatives (25F-, 25C-, 25B-, and
25I-NBOMe) (2a−d) in a single run. Both detection systems
were reproducible and sensitive, as the detection limits (LOD)
reported herein are low enough for the detection of the target
analytes in conﬁscated blotter papers. Also, the availability of
instrumentation and the cost-eﬀectiveness are a noted
advantage if compared with expensive mass detectors, as
normal UV detectors can be used in the case of detection
system I because quantiﬁcation was done at a single
wavelength (λmax = 205 nm), while detection system II
employs commercially available impinging jet ﬂow cell
incorporating SPEs, which are single shot (disposable), mass-
produced, and of economic prices. However, hyphenated
methodologies coupled to MS (e.g., LC−MS and GC−MS)
are indispensable tools that cannot be substituted with the
developed method for the analysis of seized blotters in forensic
laboratories. This is due to the fact that these blotters usually
contain untargeted compounds, which can be primarily
screened and detected with mass spectroscopy, while the
presented methodology can be used as a ﬁnal conclusive
conﬁrmation of the presence of NBOMe in blotter papers. The
selectivity and the speciﬁcity of the proposed methodology
were tested by analyzing the studied drug mixture in the
presence of LSD, common adulterants found in street samples
(i.e., caﬀeine, paracetamol, and benzocaine), and pharmaceut-
ical excipients, and none of them interfered with the
determination of the analytes of interest, demonstrating the
high selectivity of the method. Moreover, the proposed
method was successfully applied for the analysis of
laboratory-prepared (simulated) blotter papers, and the
percentage recoveries obtained showed acceptable levels of
accuracy and precision, which can make this protocol the one
of choices for the routine analysis of the studied drugs in
forensic and quality control labs after prior screening by mass
spectroscopy.
■ EXPERIMENTAL SECTION
Chemicals and Materials. All reagents (2C-F·HCl, 2C-C·
HCl, 2C-B·HCl, 2C-I·HCl, 2-methoxybenzaldehyde, triethyl-
amine, and sodium borohydride) were of commercial quality
(Sigma-Aldrich, Gillingham, U.K., or Fluorochem Limited,
Hadﬁeld, U.K.) and used without further puriﬁcation. Lysergic
acid diethylamide (LSD, 3) was obtained from LGC GmbH
(Luckenwalde, Germany) and used without any further
puriﬁcation. Solvents (Fisher Scientiﬁc, Loughborough, U.K.)
were dried, where necessary, using standard procedures.48 The
target compounds (2a−d) were synthesized from their
corresponding phenethylamine hydrochlorides (1a−d), using
an adaptation of the method reported by Hansen et al.49 and
obtained as stable (conﬁrmed by 1H NMR and GC−MS), oﬀ-
white powders. The hydrochloride salts were determined to be
soluble (10 mg mL−1) in deionized water, methanol, and
dimethyl sulfoxide. To ensure authenticity of the materials
utilized in this study, the synthesized samples were structurally
characterized (see the Supporting Information) by high-ﬁeld
NMR, FTIR, and GC−EI-MS. The purity of all samples was
conﬁrmed by both NMR and GC−EI-MS (>99.5% in all
cases). 1H NMR and 13C NMR spectra (10 mg/600 μL in
MeOH-d4) were acquired on a JEOL AS-400 (JEOL, Tokyo,
Japan) NMR spectrometer operating at a proton resonance
frequency of 400 MHz and referenced to the residual solvent
peak (MeOH-d4:
1H NMR δ = 3.31 ppm, 13C NMR δ = 49.00
ppm50). All samples were ﬁltered prior to analysis. Infrared
spectra were obtained in the range of 4000−400 cm−1 using a
Thermo Scientiﬁc Nicolet iS10ATR-FTIR instrument (Ther-
mo Scientiﬁc, Rochester). GC−MS analysis was performed
using an Agilent 7890B GC and an MS5977B mass selective
detector (Agilent Technologies, Wokingham, U.K.). The mass
spectrometer was operated in the electron ionization mode at
70 eV. Separation was achieved with a capillary column (HP5
MS, 30 mÅ, ∼0.25 mm, i.d. 0.25 μm) with helium as the
carrier gas at a constant ﬂow rate of 1.2 mL min−1. A 2 μL
aliquot of the samples was injected with a split ratio of 50:1.
Both the injector and the GC interface temperatures were
maintained at 280 °C. Oven temperature program: 50 °C
(hold for 3 min) → 50−320 °C (30 °C min−1) → 320 °C
(hold for 6 min). The MS source and quadrupole temperatures
were set at 230 and 150 °C, respectively. Mass spectra were
obtained in full-scan mode (50−550 amu). All samples were
prepared as 1 mg mL−1 solutions in methanol with no
derivatization and analyzed individually. Eicosane (1 mg
mL−1) was used as an internal standard, and each sample
was injected six times.
All aqueous solutions were prepared with Milli-Q deionized
water of resistivity ≥18.2 Ω cm (Millipore system). All
solutions (unless stated otherwise) were vigorously degassed,
for 10 min, with highly pure nitrogen to remove oxygen prior
to analysis.
Instrumentation. High-Performance Liquid Chromatog-
raphy-Photodiode Array Detection (HPLC-DAD) (Detection
System I). Reverse-phase HPLC was performed with an
Agilent HP series 1100 liquid chromatography instrument
(Agilent Technologies, Wokingham, U.K.). It consisted of an
Agilent 1100 series quaternary pump G1310A (serial
DE80301064), which comprises a solvent cabinet, an Agilent
1100 series vacuum degasser G1322A (serial JP73017007),
and an Agilent 1100 series photodiode array detector G1315A
(serial DE74603601), which was set at 205 nm. The LC
system was equipped with an Agilent 1100 series thermostated
column compartment G1316A (serial DE91810205) set to 60
°C and a 100-place autoinjector G1313A (serial
DE54901543), with an injection volume of 10.0 μL. The
analytical column used was an ACE C18-AR column (150 ×
4.6 mm2 i.d., particle size: 5 μm), Hichrom Ltd., U.K. The
mobile phase consisted of 30:70% (v/v) of 5 mM ammonium
formate and 100 mM potassium chloride buﬀer (pH 7.0):
acetonitrile, ﬂowing at a rate of 2.5 mL min−1. The total run
time was 10 min. The LC system was controlled by Agilent
Chemstation (ver. 10.02) software (Agilent Technologies,
Wokingham, U.K.) for data analysis.
High-Performance Liquid Chromatography-Amperomet-
ric Detection (HPLC-AD) (Detection System II). The HPLC
was coupled, in sequence, to a ﬂow cell obtained from
Metrohm UK, Runcorn, U.K. (impinging jet ﬂow cell; product
code: DRP-FLWCL-TEF-71306; 3.3 × 6.0 × 3.3 cm3, ﬂow
chamber volume = 8 μL), housing the SPE to give the HPLC-
AD system. The connection between the DAD and the ﬂow
cell was achieved via PTFE tubing (230 × 1.6 mm2, i.d. 0.3
mm, internal volume: 16.25 μL). The SPEs utilized in this part
of the study were fabricated in-house, as previously
described,42,51 and consisted of a 3.1 mm diameter graphite
working electrode, a graphite counter electrode, and a Ag/
AgCl reference electrode. Amperometric measurements were
carried out using an EmStat 3 potentiostat/galvanostat
(PalmSens BV, The Netherlands) and controlled by PSTrace
(version 4.4) software (PalmSens, The Netherlands). All of the
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amperometric measurements were carried out using the
following parameters: (i) potential (E, +1.0 V); (ii)
equilibration time (tequibriation, 10.0 s); (iii) data interval (tinterval,
0.08 s); (iv) current range (100 nA to 1 mA); and (iv) total
run time (trun, 5000 s). A new SPE was used for each
experiment performed. Buﬀer pH measurements were made
using a “SevenCompact pH/Ion S220” (Mettler-Toledo AG,
Switzerland) pH meter.
Preparation of the Mobile Phase [5 mM Ammonium
Formate−100 mM Potassium Chloride Buﬀer (pH 7.0):
Acetonitrile, 70:30% v/v]. The 5 mM ammonium formate−
100 mM potassium chloride buﬀer was prepared in a 2.0 L
volumetric ﬂask, by dissolving 0.6306 g of ammonium formate
and 14.91 g of potassium chloride into ultrapure deionized
water, and then the pH was adjusted to 7.0 (±0.02) with 0.2 M
NaOH. Afterwards, appropriate proportions of each of the
aqueous phase (1.4 L) and the organic modiﬁer (0.6 L) were
mixed to obtain a 2.0 L mobile phase of the desired ratio.
Finally, the mobile phase was vacuum-ﬁltered through a 0.45
mm pore ﬁlter paper.
Preparation of Standard Stock Solution and Calibration
Curve Working Solutions for HPLC. Each NBOMe derivative
(10.0 mg, 2a−d) was weighted accurately into one 20.0 mL
glass volumetric ﬂask and diluted to volume with the mobile
phase to give a stock solution (S) containing 0.5 mg mL−1 of
each drug. Working solutions for calibration standards were
prepared by further dilution of the latter solution (S) with the
mobile phase to obtain concentrations of 10, 20, 50, 100, 150,
200, and 300 μg mL−1 of each analyte. Working solutions were
injected directly into the HPLC, and the peak areas (for the
HPLC-DAD analysis) and peak heights (for the HPLC-AD
analysis) of the target drugs were plotted against their
corresponding concentrations to construct the calibration
curves.
Selectivity Standards. Lysergic Acid Diethylamide (LSD).
LSD (5.0 mg) was weighed into a 10.0 mL glass volumetric
ﬂask and diluted to volume with the mobile phase to get a
stock solution of concentration 0.5 mg mL−1 of the drug. The
latter solution (1.0 mL) was transferred to a 5.0 mL volumetric
ﬂask, and the solution was made to the mark with the mobile
phase and injected into the HPLC to monitor the retention
time (tR) of LSD alone. Another 1.0 mL of the LSD stock
solution was transferred to a 5.0 mL volumetric ﬂask
containing 1.0 mL of the NBOMe standard stock solution
(S), and the ﬂask was made to the mark with the mobile phase
and injected into the HPLC to test the possibility of LSD
interference with the determination of the four NBOMe
derivatives.
Adulterants commonly found in street samples (para-
cetamol, caﬀeine, and benzocaine): refer to the Supporting
Information (SI).
Speciﬁcity standards: refer to the Supporting Information
(SI).
Forensic Application. Application of the Method to
Simulated Blotter Papers. Three blotter papers (A4 white
sheet blotters purchased from Amazon, U.K.) were laboratory-
prepared and analyzed using the proposed method as follows:
blotter papers were cut into pieces with dimensions 1 × 1 cm2;
then, nine blotter papers were soaked into three diﬀerent vials
(each three blotters were soaked into one vial), and each vial
contained 2.0 mL of the following solutions: vial 1 had 200 μg
mL−1 LSD and 600 μg mL−1 25I-NBOMe (2d), vial 2
contained 100 μg mL−1 LSD, 500 μg mL−1 25I-NBOMe (2d),
and 600 μg mL−1 25C-NBOMe (2b), and vial 3 had 500 μg
mL−1 25B-NBOMe (2c). The blotter papers were kept
submerged into the solutions in the vials overnight; the next
day, the contents in the blotter papers were extracted by
transferring each blotter paper to an Eppendorf containing 1.0
mL methanol and sonicated it in an ultrasonic bath for 20 min.
Finally, the obtained solutions were diluted to half with the
mobile phase to get concentrations of the drugs within the
linearity ranges and injected into the HPLC. Standard addition
solutions were prepared by a twofold dilution of the latter
sample solutions with the mobile phase and then spiking them
with known portions of 25I-NBOMe (2d) and/or 25C-
NBOMe (2b) and/or 25B-NBOMe (2c) standard solutions to
obtain total concentrations within the speciﬁed linearity
ranges, and then the solutions were injected into the HPLC.
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